Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MYO5C

Gene summary for MYO5C

Gene summary.

Gene information	Species	Human
	Gene symbol	MYO5C
	Gene ID	55930
	Gene name	myosin VC
	Gene Alias	MYO5C
	Cytomap	15q21.2
	Gene Type	protein-coding
	GO ID	GO:0006810
	UniProtAcc	Q9NQX4

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
55930	MYO5C	HTA11_3410_2000001011	Human	Colorectum	AD	2.63e-03	-2.85e-01	0.0155
55930	MYO5C	HTA11_347_2000001011	Human	Colorectum	AD	2.08e-04	4.90e-01	-0.1954
55930	MYO5C	HTA11_99999971662_82457	Human	Colorectum	MSS	2.38e-10	-4.29e-01	0.3859
55930	MYO5C	HTA11_99999974143_84620	Human	Colorectum	MSS	1.56e-09	-4.07e-01	0.3005
55930	MYO5C	F007	Human	Colorectum	FAP	1.16e-05	-3.64e-01	0.1176
55930	MYO5C	A001-C-207	Human	Colorectum	FAP	2.61e-06	-2.00e-01	0.1278
55930	MYO5C	A015-C-203	Human	Colorectum	FAP	3.06e-33	-4.58e-01	-0.1294
55930	MYO5C	A015-C-204	Human	Colorectum	FAP	1.05e-07	-2.63e-01	-0.0228
55930	MYO5C	A014-C-040	Human	Colorectum	FAP	5.49e-08	-4.68e-01	-0.1184
55930	MYO5C	A002-C-201	Human	Colorectum	FAP	2.16e-17	-2.65e-01	0.0324
55930	MYO5C	A002-C-203	Human	Colorectum	FAP	9.55e-09	-1.91e-01	0.2786
55930	MYO5C	A001-C-119	Human	Colorectum	FAP	1.46e-06	-5.02e-03	-0.1557
55930	MYO5C	A001-C-108	Human	Colorectum	FAP	6.20e-20	-1.57e-01	-0.0272
55930	MYO5C	A002-C-205	Human	Colorectum	FAP	6.41e-27	-1.55e-01	-0.1236
55930	MYO5C	A001-C-104	Human	Colorectum	FAP	4.49e-03	-9.50e-02	0.0184
55930	MYO5C	A015-C-005	Human	Colorectum	FAP	4.20e-03	6.24e-03	-0.0336
55930	MYO5C	A015-C-006	Human	Colorectum	FAP	7.58e-18	-2.73e-01	-0.0994
55930	MYO5C	A015-C-106	Human	Colorectum	FAP	5.76e-17	-1.64e-01	-0.0511
55930	MYO5C	A002-C-114	Human	Colorectum	FAP	6.53e-22	-2.16e-01	-0.1561
55930	MYO5C	A015-C-104	Human	Colorectum	FAP	1.56e-36	-2.44e-01	-0.1899

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00070158	Lung	IAC	actin filament organization	92/2061	442/18723	1.01e-09	1.93e-07	92
GO:00307056	Lung	IAC	cytoskeleton-dependent intracellular transport	40/2061	195/18723	7.30e-05	1.54e-03	40
GO:00300486	Lung	IAC	actin filament-based movement	27/2061	127/18723	5.70e-04	7.89e-03	27
GO:00516506	Lung	IAC	establishment of vesicle localization	32/2061	161/18723	6.53e-04	8.87e-03	32
GO:00516566	Lung	IAC	establishment of organelle localization	64/2061	390/18723	7.12e-04	9.50e-03	64
GO:00516486	Lung	IAC	vesicle localization	34/2061	177/18723	8.53e-04	1.09e-02	34
GO:00995156	Lung	IAC	actin filament-based transport	8/2061	21/18723	1.16e-03	1.35e-02	8
GO:00300506	Lung	IAC	vesicle transport along actin filament	7/2061	19/18723	2.95e-03	2.61e-02	7
GO:000701513	Lung	AIS	actin filament organization	88/1849	442/18723	1.02e-10	3.13e-08	88
GO:003070512	Lung	AIS	cytoskeleton-dependent intracellular transport	37/1849	195/18723	7.68e-05	1.95e-03	37
GO:005165012	Lung	AIS	establishment of vesicle localization	31/1849	161/18723	2.15e-04	4.36e-03	31
GO:005164812	Lung	AIS	vesicle localization	33/1849	177/18723	2.56e-04	4.96e-03	33
GO:009951512	Lung	AIS	actin filament-based transport	8/1849	21/18723	5.58e-04	8.73e-03	8
GO:003004812	Lung	AIS	actin filament-based movement	25/1849	127/18723	5.99e-04	9.14e-03	25
GO:005165612	Lung	AIS	establishment of organelle localization	59/1849	390/18723	6.08e-04	9.24e-03	59
GO:003005012	Lung	AIS	vesicle transport along actin filament	7/1849	19/18723	1.57e-03	1.83e-02	7
GO:000701533	Lung	MIAC	actin filament organization	50/967	442/18723	1.64e-07	3.81e-05	50
GO:009951522	Lung	MIAC	actin filament-based transport	6/967	21/18723	5.19e-04	1.37e-02	6
GO:003004831	Lung	MIAC	actin filament-based movement	16/967	127/18723	8.47e-04	1.83e-02	16
GO:005165622	Lung	MIAC	establishment of organelle localization	35/967	390/18723	1.09e-03	2.16e-02	35

Page: 1 2 3 4

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05130	Colorectum	AD	Pathogenic Escherichia coli infection	79/2092	197/8465	1.05e-06	1.36e-05	8.65e-06	79
hsa051301	Colorectum	AD	Pathogenic Escherichia coli infection	79/2092	197/8465	1.05e-06	1.36e-05	8.65e-06	79
hsa051304	Colorectum	MSS	Pathogenic Escherichia coli infection	73/1875	197/8465	1.10e-06	1.48e-05	9.06e-06	73
hsa051305	Colorectum	MSS	Pathogenic Escherichia coli infection	73/1875	197/8465	1.10e-06	1.48e-05	9.06e-06	73
hsa051308	Colorectum	FAP	Pathogenic Escherichia coli infection	62/1404	197/8465	1.37e-07	3.08e-06	1.87e-06	62
hsa051309	Colorectum	FAP	Pathogenic Escherichia coli infection	62/1404	197/8465	1.37e-07	3.08e-06	1.87e-06	62
hsa0513010	Colorectum	CRC	Pathogenic Escherichia coli infection	47/1091	197/8465	1.49e-05	3.84e-04	2.60e-04	47
hsa0513011	Colorectum	CRC	Pathogenic Escherichia coli infection	47/1091	197/8465	1.49e-05	3.84e-04	2.60e-04	47
hsa05130211	Esophagus	ESCC	Pathogenic Escherichia coli infection	142/4205	197/8465	8.21e-11	1.06e-09	5.42e-10	142
hsa05130310	Esophagus	ESCC	Pathogenic Escherichia coli infection	142/4205	197/8465	8.21e-11	1.06e-09	5.42e-10	142
hsa0513016	Lung	IAC	Pathogenic Escherichia coli infection	45/1053	197/8465	2.93e-05	6.14e-04	4.08e-04	45
hsa0513017	Lung	IAC	Pathogenic Escherichia coli infection	45/1053	197/8465	2.93e-05	6.14e-04	4.08e-04	45
hsa0513023	Lung	AIS	Pathogenic Escherichia coli infection	42/961	197/8465	3.43e-05	5.62e-04	3.59e-04	42
hsa0513033	Lung	AIS	Pathogenic Escherichia coli infection	42/961	197/8465	3.43e-05	5.62e-04	3.59e-04	42
hsa04814	Lung	MIAC	Motor proteins	21/507	193/8465	5.64e-03	3.82e-02	2.76e-02	21
hsa048141	Lung	MIAC	Motor proteins	21/507	193/8465	5.64e-03	3.82e-02	2.76e-02	21

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MYO5C

SNV

Missense_Mutation

c.4616N>A

p.Ser1539Asn

p.S1539N

Q9NQX4

protein_coding

deleterious(0.03)

probably_damaging(0.968)

TCGA-A8-A07R-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Ancillary

zoledronic

MYO5C

SNV

Missense_Mutation

c.4133T>C

p.Leu1378Pro

p.L1378P

Q9NQX4

protein_coding

deleterious(0)

probably_damaging(0.973)

TCGA-A8-A09Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO5C

SNV

Missense_Mutation

c.1666G>C

p.Glu556Gln

p.E556Q

Q9NQX4

protein_coding

tolerated(0.06)

benign(0.444)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO5C

SNV

Missense_Mutation

c.4786N>A

p.Asp1596Asn

p.D1596N

Q9NQX4

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-BH-A0BP-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO5C

SNV

Missense_Mutation

c.2809G>A

p.Ala937Thr

p.A937T

Q9NQX4

protein_coding

tolerated(0.72)

benign(0.001)

TCGA-BH-A1F8-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

MYO5C

SNV

Missense_Mutation

c.3583G>A

p.Glu1195Lys

p.E1195K

Q9NQX4

protein_coding

tolerated(0.28)

benign(0.044)

TCGA-C8-A1HM-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

doxorubicin

MYO5C

deletion

Frame_Shift_Del

novel

c.4963delN

p.Tyr1655ThrfsTer13

p.Y1655Tfs*13

Q9NQX4

protein_coding

TCGA-EW-A2FV-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

docetaxel

MYO5C

SNV

Missense_Mutation

rs771283105

c.4607N>A

p.Arg1536His

p.R1536H

Q9NQX4

protein_coding

deleterious(0)

probably_damaging(0.985)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

MYO5C

SNV

Missense_Mutation

novel

c.4465N>A

p.Leu1489Ile

p.L1489I

Q9NQX4

protein_coding

deleterious(0.05)

benign(0.176)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

MYO5C

SNV

Missense_Mutation

novel

c.2396N>A

p.Ala799Asp

p.A799D

Q9NQX4

protein_coding

tolerated(0.21)

benign(0.092)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1